A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
- To investigate the safety of once-daily repeated transdermal administration of SPM 962
within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's
disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label
uncontrolled study.
- To investigate efficacy of SPM 962 in an exploratory manner.